InMed $IN Files Patent for Pain Treatment Program

InMed Pharma(CSE: IN; OTCQB: IMLFF)

InMed Pharmaceuticals, Inc, a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the filing of a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the company’s intellectual and commercial property.

While there are numerous pharmaceutical products to treat both acute and chronic pain, the increase in the number of prescriptions for the opioid class of products (oxycodone, hydrocodone, morphine, methadone, fentanyl, etc.) has led to concerns as these products can be highly addictive and have damaging side effects, including death.

According to the United States Centers for Disease Control and Prevention, drug overdose deaths continue to increase in the United States, with the majority (more than 60%) involving an opioid. Since 1999, the number of overdose deaths involving opioids (including prescription opioids and heroin) quadrupled, as have the number of prescriptions for opioids, yet there has been no increase in the amount of pain reported in the general population.  Thus, there is a need to find alternatives to treat chronic and severe pain that are non-addictive and have limited side effects. InMed is researching the potential of non-THC (tetrahydrocannabinol, a psychoactive ingredient in cannabis) cannabinoids to treat pain using a proprietary topical formulation.

“There remains a significant need in the field of analgesia for a product that can treat pain via a topical route of administration, which would reduce systemic exposure and any associated side effects. InMed’s focus on non-psychoactive cannabinoids further reduces concerns regarding addiction, a key concern in pain management.”

-Dr. Sazzad Hossain, Chief Scientific Officer of InMed Pharmaceuticals and a Co-inventor on the patent

InMed’s study results published earlier this year by InMed in the European Journal of Pain (NR July 27, 2017 ) highlighted the topical application of THC to successfully treat peripheral pain.  The foundation of this patent is the unreported data on non-THC cannabinoids and their ability to modulate pain.  The patent cites a range of cannabinoids, alone or in combination, applied topically to treat various types of pain – muscle, nerve, arthritis-induced joint pain, etc.